MedTrace Logo

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT04004221 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

This was a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the anti- programmed cell death-1(PD-1) monoclonal antibody BGB-A317 in participants with PD-L1+, locally advanced or metastatic Urothelial Bladder Cancer (UBC) who have progressed during or following a platinum-containing regimen

Conditions

  • Locally Advanced or Metastatic Urothelial Bladder Cancer

Interventions

DRUG

Tislelizumab

200mg intravenously (IV) every 3 weeks (Q3W)

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-16
Primary Completion
2019-09-16
Completion
2021-03-11

Countries

  • China
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04004221 on ClinicalTrials.gov